Diabetes Masters Registration

Program Faculty

Jack Leahy, MD - Program Chair

Professor of Medicine
Chief, Division of Endocrinology,
Diabetes and Metabolism
The University of Vermont
Colchester, Vermont

Lawrence Blonde, MD, FACP, FACE

Director, Ochsner Diabetes Clinical Research Unit
Department of Diabetes, Endocrinology and Metabolism
Associate Director, Internal Medicine Residency Program
Ochsner Medical Center
New Orleans, Louisiana

Scott V Joy, MD, FACP

Associate Professor of Medicine
Medical Director, Duke Primary Care
Duke University Health System
Durham, North Carolina

Thomas Repas, DO, FACP, FACOI, FACE, CDE

Clinical Assistant Professor
Department of Medicine
Sanford School of Medicine
The University of South Dakota
Rapid City, South Dakota

Due to the program structure and format, space is limited and preregistration is required.

Program Overview
Analyses of current trends indicate that diabetes prevalence could reach nearly 30% by 2050, with the vast majority of patients (90%-95%) affected by type 2 diabetes (T2D). Despite the availability of at least 12 classes of agents to manage hyperglycemia in patients with T2D, up to two-thirds of patients are not meeting glycemic goals. The progressive nature of T2D and limitations of available agents (eg, lack of durability, adverse effects) may contribute to this poor outcome. To address the mounting therapeutic needs of this patient population, increased knowledge of T2D pathophysiology has been leveraged toward the development of therapeutic agents that facilitate a more comprehensive approach to the management of this disease. The resulting wealth of patient-centered clinical research is generating options that may replace or augment available treatments to create more effective and safer regimens. However, it may be difficult for clinicians to stay abreast of the abundance of current evidence. Accordingly, this educational activity will focus on recent advances in T2D, including insulin therapy, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose co-transporter 2 (SGLT2) inhibitors.

Intended Audience
The proposed activity is intended for diabetes specialists, including endocrinologists, certified diabetes educators, and primary care physicians and nurses with extensive experience managing patients with T2D.

Learning Objectives
At the conclusion of this activity, participants should be able to:

Outline the current standards of care for patients with T2D
Discuss limitations of traditional therapies in helping patients achieve glycemic goals
Explain the role new agents have in surmounting current therapeutic challenges and individualizing care for patients with T2D
Assess the current clinical evidence for new and emerging agents for the treatment of T2D
Summarize recent developments in the treatment of T2D for presentation to colleagues

CME/CE Accreditation and Statements
Physicians
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nurses
The Institute for Medical and Nursing Education, Inc (IMNE) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC's) Committee on Accreditation.

IMNE designates this educational activity for 4.5 contact hours (0.45 CEUs). Accreditation by the ANCC's Committee on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Diabetes Educators
ANCC-accredited providers have been approved by the National Certification Board for Diabetes Educators (NCBDE) as providers of continuing education (CE). Individuals seeking recertification from the NCBDE can use the CE contact hours received through participation in this activity.

Commercial Support Acknowledgment
Supported by educational grants from Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc, and Lilly, USA, LLC; Boehringer Ingelheim Pharmaceuticals, Inc, made possible in part through a collaboration with Eli Lilly and Company; Bristol-Myers Squibb and AstraZeneca Pharmaceuticals LP, Alliance Partners; and Novo Nordisk, Inc.

Americans with Disabilities Act Compliance
IMNE is fully compliant with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If you are in need of accommodations, please contact Katie Fidanza at katie.fidanza@imne.com or via phone at +1 404 443 1511.